Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan.

Stefan Kohler Norman Sitali Jay Achar Nicolas Paul

Published in: ERJ open research (2022)

Introducing new and shorter TB drug regimens could increase the cost of TB programmes with low drug resistance rates and decrease the cost of TB programmes with high drug resistance rates.

Keyphrases

mycobacterium tuberculosis
adverse drug
drug induced
randomized controlled trial
pulmonary tuberculosis
hiv aids
hepatitis c virus
human immunodeficiency virus
hiv infected